Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for April 2011. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Use of Ciliary Neurotrophic Factor Slows Vision Loss
MONDAY, April 18 (HealthDay News) -- Ciliary neurotrophic factor (CNTF) treatment shows promise for slowing the progression of vision loss in people with a type of age-related macular degeneration -- geographic atrophy (GA), according to the results of a phase 2 clinical trial published in the April 12 issue of the Proceedings of the National Academy of Sciences.
Adalimumab Maintains Remission of Childhood Uveitis
MONDAY, April 18 (HealthDay News) -- Children with noninfectious childhood uveitis are more likely to remain in remission when treated with adalimumab compared to infliximab, according to a study published in the April issue of Arthritis Care & Research.
Asian Americans Face Higher Glaucoma Risk
THURSDAY, April 14 (HealthDay News) -- Asian Americans may be at greater risk for glaucoma compared to other races in the United States, according to a study published online Feb. 10 in Ophthalmology.
Vitamin D Levels May Reduce Risk of Macular Degeneration
WEDNESDAY, April 13 (HealthDay News) -- Serum 25-hydroxyvitamin D (25[OH]D) concentrations may be associated with a reduced likelihood of developing early age-related macular degeneration (AMD) in women younger than 75 years, according to a study published in the April issue of the Archives of Ophthalmology.
'Global Trigger Tool' Identifies 10 Times More Errors
THURSDAY, April 7 (HealthDay News) -- Use of the new Global Trigger Tool, developed by the Institute for Healthcare Improvement, detects at least 10 times more adverse events than other methods currently in use, according to a study published in the April issue of Health Affairs.
Copyright © 2011 ScoutNews, LLC. All rights reserved.
|Previous: April 2011 Briefing - Hematology & Oncology||Next: April 2011 Briefing - Orthopedics|
Reader comments on this article are listed below. Review our comments policy.